Verrica Pharmaceuticals’ (VRCA) Buy Rating Reaffirmed at HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $12.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 98.02% from the company’s current price.

VRCA has been the topic of a number of other reports. Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Zacks Research raised Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $14.50.

Verrica Pharmaceuticals Stock Performance

Shares of Verrica Pharmaceuticals stock opened at $6.06 on Tuesday. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The company has a quick ratio of 1.98, a current ratio of 2.10 and a debt-to-equity ratio of 0.03. The company’s 50-day simple moving average is $6.09 and its 200-day simple moving average is $6.45. The firm has a market cap of $104.11 million, a price-to-earnings ratio of -5.88 and a beta of 1.54.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. The business had revenue of $5.02 million for the quarter, compared to analyst estimates of $4.51 million. As a group, equities research analysts anticipate that Verrica Pharmaceuticals will post -1.84 earnings per share for the current year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its position in shares of Verrica Pharmaceuticals by 22.6% in the 1st quarter. Renaissance Technologies LLC now owns 32,360 shares of the company’s stock worth $171,000 after buying an additional 5,960 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth about $122,000. Quadrature Capital Ltd purchased a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth about $99,000. Man Group plc purchased a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth about $94,000. Finally, Armistice Capital LLC boosted its position in shares of Verrica Pharmaceuticals by 75.1% in the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock worth $9,298,000 after buying an additional 479,732 shares in the last quarter. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.